Home » Newsletters » BioWorld Science

BioWorld Science

May 22, 2018

View Archived Issues

Bayer patents Wnt signaling and/or tankyrase-1/2 inhibitors

Accent Therapeutics launches to create innovative therapeutics in area of epitranscriptomics

Docetaxel nanoemulsion with theranostic properties selectively targets ovarian cancer cells

Wuhan Bowo Biological Technology divulges pneumococcal protein vaccines

FDA approves thrombopoietin receptor agonist Doptelet

European Commission approves Juluca for HIV-1

FDA awards breakthrough therapy and fast track designations to Harmony's pitolisant

Prolia approved in U.S. for glucocorticoid-induced osteoporosis

Lundbeck begins clinical development with PDE1 inhibitor Lu-AF-76432

New anticancer adaptive cell therapy approach as cancer immunotherapeutic shows promise

FDA approves Lokelma for hyperkalemia

KRAS-G12C inhibitors reveal new approach to undruggable targets

FDA accepts NDA for Rifamycin SV MMX

Merck & Co.'s rVSV-ZEBOV Ebola vaccine deployed in Democratic Republic of Congo

Immunomedics submits BLA for sacituzumab govitecan for metastatic TNBC

Genentech presents first phase I data for BITS-7201A

AstraZeneca files for Japanese approval of Forxiga for type 1 diabetes

MHRA clears 4D pharma to begin phase Ib study of MRx-0518

First-in-human study shows promise of SYNT-001 in pemphigus

Glenmark submits NDA for Ryaltris for seasonal allergic rhinitis

Allergy Therapeutics reports promising topline results from phase II trial of Grass MATA MPL

New company Curevo to support GC Pharma's vaccine development work

Gilead Sciences seeks Japanese approval of sofosbuvir/velpatasvir

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...